Production (Stage)
Monopar Therapeutics Inc.
MNPR
$37.11
-$0.905-2.38%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 37.25% | 94.72% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -70.91% | 603.19% | |||
| Operating Income | 70.91% | -603.19% | |||
| Income Before Tax | 75.97% | -737.66% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 75.97% | -737.66% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 75.97% | -737.66% | |||
| EBIT | 70.91% | -603.19% | |||
| EBITDA | -- | -- | |||
| EPS Basic | 83.14% | -501.46% | |||
| Normalized Basic EPS | 83.14% | -501.38% | |||
| EPS Diluted | 83.14% | -501.46% | |||
| Normalized Diluted EPS | 83.14% | -501.38% | |||
| Average Basic Shares Outstanding | 42.52% | 39.27% | |||
| Average Diluted Shares Outstanding | 42.52% | 39.27% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||